Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDNA NASDAQ:NTRA NYSE:NVTA NASDAQ:RDNT NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDNACareDx$29.19$23.24$10.96▼$30.00$1.51B2.43906,816 shs855,904 shsNTRANatera$279.32$219.79$131.81▼$279.63$40.00B1.511.57 million shs1.27 million shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shsN/ARDNTRadNet$68.75$56.57$50.76▼$85.84$5.41B1.371.04 million shs1.69 million shsVCYTVeracyte$57.08$46.27$22.61▼$60.91$4.55B1.931.42 million shs1.15 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDNACareDx0.00%+1.28%+30.84%+59.42%+49.77%NTRANatera0.00%+6.65%+31.85%+34.30%+72.88%NVTAInvitae0.00%0.00%0.00%0.00%0.00%RDNTRadNet0.00%+13.19%+32.54%+25.48%+23.54%VCYTVeracyte0.00%-5.64%+17.23%+76.99%+106.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDNACareDx$29.19$23.24$10.96▼$30.00$1.51B2.43906,816 shs855,904 shsNTRANatera$279.32$219.79$131.81▼$279.63$40.00B1.511.57 million shs1.27 million shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shsN/ARDNTRadNet$68.75$56.57$50.76▼$85.84$5.41B1.371.04 million shs1.69 million shsVCYTVeracyte$57.08$46.27$22.61▼$60.91$4.55B1.931.42 million shs1.15 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDNACareDx0.00%+1.28%+30.84%+59.42%+49.77%NTRANatera0.00%+6.65%+31.85%+34.30%+72.88%NVTAInvitae0.00%0.00%0.00%0.00%0.00%RDNTRadNet0.00%+13.19%+32.54%+25.48%+23.54%VCYTVeracyte0.00%-5.64%+17.23%+76.99%+106.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDNACareDx 2.00Hold$25.00-14.35% DownsideNTRANatera 2.86Moderate Buy$260.33-6.80% DownsideNVTAInvitae 0.00N/AN/AN/ARDNTRadNet 2.90Moderate Buy$87.4327.17% UpsideVCYTVeracyte 2.56Moderate Buy$50.43-11.65% DownsideCurrent Analyst Ratings BreakdownLatest NVTA, NTRA, VCYT, RDNT, and CDNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026VCYTVeracyte GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $65.006/29/2026NTRANatera GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$270.00 ➝ $290.006/26/2026CDNACareDx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)6/26/2026NTRANatera Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$310.006/25/2026NTRANatera Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/24/2026VCYTVeracyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/24/2026NTRANatera BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$250.00 ➝ $275.006/24/2026NTRANatera UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$260.006/24/2026NTRANatera BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$280.00 ➝ $260.006/23/2026NTRANatera BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$250.00 ➝ $270.006/11/2026NTRANatera Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$275.00(Data available from 7/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDNACareDx$379.80M3.97$0.01 per share4,481.53$5.89 per share4.96NTRANatera$2.50B16.00N/AN/A$12.38 per share22.56NVTAInvitae$481.58M0.00N/AN/A$0.42 per share0.00RDNTRadNet$2.04B2.65$3.22 per share21.33$17.58 per share3.91VCYTVeracyte$517.15M8.81$1.49 per share38.32$16.57 per share3.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDNACareDx-$21.35M-$0.16N/A97.30N/A-2.01%-2.65%-1.96%8/5/2026 (Estimated)NTRANatera-$208.16M-$1.63N/AN/AN/A-9.05%-14.74%-10.27%8/6/2026 (Estimated)NVTAInvitae-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/ARDNTRadNet-$18.65M-$0.18N/A68.75N/A-0.66%2.77%0.97%8/10/2026 (Estimated)VCYTVeracyte$66.35M$1.0952.3739.92N/A16.25%9.07%8.38%8/5/2026 (Estimated)Latest NVTA, NTRA, VCYT, RDNT, and CDNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026RDNTRadNet-$0.14-$0.28-$0.14-$0.43$557.93 million$575.63 million5/5/2026Q1 2026VCYTVeracyte$0.34$0.52+$0.18$0.35$130.36 million$139.07 million4/28/2026Q1 2026CDNACareDx$0.11$0.34+$0.23$0.05$102.03 million$117.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCDNACareDxN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ANVTAInvitaeN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDNACareDxN/A3.403.07NTRANateraN/A2.962.83NVTAInvitaeN/A2.392.25RDNTRadNet0.791.171.17VCYTVeracyteN/A9.318.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDNACareDxN/ANTRANatera99.90%NVTAInvitae61.28%RDNTRadNet77.90%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipCDNACareDx2.40%NTRANatera5.05%NVTAInvitae0.74%RDNTRadNet5.60%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDNACareDx74051.66 million50.42 millionOptionableNTRANatera6,140143.22 million135.98 millionOptionableNVTAInvitae1,700267.01 million284.37 millionNo DataRDNTRadNet11,26478.63 million74.23 millionOptionableVCYTVeracyte79079.79 million78.68 millionOptionableNVTA, NTRA, VCYT, RDNT, and CDNA HeadlinesRecent News About These CompaniesVeracyte, Inc. (NASDAQ:VCYT) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 3 at 2:15 AM | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 3 at 2:13 AM | marketbeat.comVeracyte Stock Surges 117% in a Year: What's Driving the Rally?July 2 at 3:16 PM | zacks.comVeracyte (NASDAQ:VCYT) Reaches New 12-Month High - Here's WhyJuly 1 at 4:59 AM | americanbankingnews.comVeracyte (NASDAQ:VCYT) Reaches New 12-Month High - Time to Buy?June 29, 2026 | marketbeat.comWhat to Know About This $197,000 Veracyte Insider Sale After a 120% Stock RallyJune 27, 2026 | fool.comVeracyte (NASDAQ:VCYT) Stock Rating Lowered by Wall Street ZenJune 27, 2026 | americanbankingnews.comVeracyte (NASDAQ:VCYT) Downgraded by Wall Street Zen to "Buy"June 27, 2026 | marketbeat.com130,037 Shares in Veracyte, Inc. $VCYT Bought by Corient Private Wealth LLCJune 26, 2026 | marketbeat.comVeracyte (NASDAQ:VCYT) Sets New 1-Year High - Time to Buy?June 23, 2026 | americanbankingnews.comVeracyte (NASDAQ:VCYT) Director Karin Eastham Sells 3,729 SharesJune 23, 2026 | insidertrades.comAEGON ASSET MANAGEMENT UK Plc Sells 162,791 Shares of Veracyte, Inc. $VCYTJune 21, 2026 | marketbeat.comThis top stock has surged. CEO explains key to Veracyte's success.June 19, 2026 | msn.com125,000 Shares in Veracyte, Inc. $VCYT Acquired by Ardsley Advisory Partners LPJune 18, 2026 | marketbeat.comFred Alger Management LLC Sells 133,585 Shares of Veracyte, Inc. $VCYTJune 17, 2026 | marketbeat.comVeracyte (NASDAQ:VCYT) Sets New 1-Year High - Here's What HappenedJune 17, 2026 | marketbeat.comArtisan Partners Limited Partnership Sells 1,107,426 Shares of Veracyte, Inc. $VCYTJune 17, 2026 | marketbeat.comThis top biotech has surged. CEO explains key to Veracyte's success.June 17, 2026 | msn.comVeracyte (NASDAQ:VCYT) Trading Up 5.8% - What's Next?June 16, 2026 | marketbeat.comEventide Asset Management LLC Reduces Holdings in Veracyte, Inc. $VCYTJune 14, 2026 | marketbeat.comVeracyte (NASDAQ:VCYT) Hits New 12-Month High - Here's WhyJune 11, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesFlying Under the Radar: Lockheed Martin's $2.8B Stealth SetupBy Jeffrey Neal Johnson | June 17, 2026Rocket Lab's NASA Win Tests Key Support After Sharp PullbackBy Ryan Hasson | June 26, 2026MDA Space Targets US Defense Market With $620M AcquisitionBy Jeffrey Neal Johnson | June 25, 2026Satellogic Is Tiny But Its Revenue Growth Is Hard to IgnoreBy Leo Miller | June 19, 2026Viasat's Orbiting Profits: Space Force Jackpot?By Jeffrey Neal Johnson | June 14, 2026NVTA, NTRA, VCYT, RDNT, and CDNA Company DescriptionsCareDx NASDAQ:CDNA$29.19 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$29.16 -0.03 (-0.09%) As of 07/2/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Natera NASDAQ:NTRA$279.32 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$283.53 +4.21 (+1.51%) As of 07/2/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Invitae NYSE:NVTAInvitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.RadNet NASDAQ:RDNT$68.75 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$68.77 +0.02 (+0.03%) As of 07/2/2026 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.Veracyte NASDAQ:VCYT$57.08 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$57.07 -0.01 (-0.02%) As of 07/2/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus Why Kroger's Giant Eagle Deal Could Change Everything SMRs Spark a Chain Reaction for Nano Nuclear Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
